Fifty 1 Labs, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FITY research report →
Price Chart
About the company
Fifty 1 Labs, Inc. is a Nevada-based holding company that has shifted its focus to biotechnology and telehealth, centering on peptide science for musculoskeletal health, recovery, and performance. The company utilizes AI-driven research and aims to develop a telehealth platform for personalized peptide therapies.
- CEO
- Joel Gagnier
- IPO
- 2005
- Employees
- 2
- HQ
- Melbourne, FL, US
Get TickerSpark's AI analysis on FITY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $114.38K
- P/E
- -0.96
- PEG
- -0.01
- P/S
- 2433.53
- P/B
- -0.30
- EV/EBITDA
- -1.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -358397.87%
- Net Margin
- -523204.26%
- ROE
- 72.68%
- ROIC
- 26.86%
Latest fiscal year · YoY change
- Revenue
- $47+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-168,448
- Net Income
- $-245,906+31.5%
- EPS
- $0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.66
- RSI (14)
- 46
- Avg Volume
- 16.26M
No earnings-call transcripts are available for FITY yet.
- Free Float
- 1.5%
- Shares Outstanding
- 571.88M
- Float Shares
- 8.71M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 31, 07 | SEVERSON MARK A | other | 0 |
| Dec 31, 07 | SEVERSON MARK A | other | 0 |
| Dec 31, 07 | SEVERSON MARK A | other | 0 |
| Dec 31, 07 | SEVERSON MARK A | other | 0 |
| Oct 1, 07 | SEVERSON MARK A | other | 0 |
| Mar 31, 07 | SEVERSON MARK A | other | 312 |
| Mar 20, 07 | SEVERSON MARK A | other | 997 |
| Jan 31, 07 | SEVERSON MARK A | buy | 1,000 |
| Jan 23, 07 | SEVERSON MARK A | other | 1,365 |
| Mar 13, 06 | SEVERSON MARK A | buy | 980 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FITY coverage
Recent articles, reports, and earnings notes.
No research on FITY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FITY report →Fifty 1 Labs, Inc. Acquires MSK Signal Recovery Product Line to Accelerate Growth in the Peptide and Musculoskeletal Health Market
accessnewswire.com · Aug 26
Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform
accessnewswire.com · Aug 7
Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth
accessnewswire.com · Jul 10
Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health
accessnewswire.com · Apr 15
Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market
accessnewswire.com · Apr 14
Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace
globenewswire.com · Jan 5
Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer
globenewswire.com · Oct 9
Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.